Boston Scientific (NYSE:BSX) today shared new findings supporting intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI).
Marlborough, Massachusetts-based Boston Scientific shared findings from the DK-CRUSH VIII trial at ACC 2026 in New Orleans. It looked at the double kissing (DK) crush technique with the company’s Synergy drug-eluting stent implantation using IVUS.
The DK-CRUSH VIII trial marks the first-ever “adequately powered” randomized clinical trial for IVUS-guided vs. angio-guided PCI in complex bifurcation lesions using the DK crush technique, the company said in a LinkedIn post. It found that IVUS use led to a 60% reduction in target vessel failure at one year.
Boston Scientific said the study took place across 24 centers in China, evaluating 555 patients. It had a primary endpoint of a composite of target vessel failure. Investigators defined that as cardiac death, target vessel myocardial infarction, or clinically driven target vessel revascularization at one year.
A total of 124 patients in the IVUS arm (44.8%) and 122 (43.9%) in the angio-guided group had a bifurcation lesion involving the left main coronary artery. Investigators used DK crush. in 96.8% of patients. At one year, a primary endpoint event occured in 17 patients (6.1%) in the IVUS group and 41 patients (14.7%) in the angiography group.
Additionally, Boston Scientific reported 75.4% post-stent optimization in the IVUS-guided arm. The company said results reinforce that IVUS-guided PCI improves patient outcomes.
Boston Scientific shared additional data at ACC supporting its cardiology technology. That includes studies for the Watchman FLX device and the EKOS endovascular system.
